Healthcare workers might not be so different from the general population in the factors that determine their risk of getting COVID-19. A new study led by Cedars-Sinai shows that healthcare workers are more likely to have antibodies to COVID-19 in their blood if they are African American or Latino or have hypertension.
La Jolla Institute for Immunology (LJI), one of the leading research organizations dedicated to studying the immune system announced today that it has signed a licensing agreement with Leinco Technologies, Inc., a premier developer and manufacturer of leading-edge recombinant proteins, antibodies, and conjugates.
MEDIA ADVISORY Paper title: SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study Corresponding Author: Stuart C. Sealfon, MD, Professor of Neurology, Neuroscience and Pharmacological Sciences, Icahn School of Medicine at Mount Sinai Bottom Line: Although…
Earlier this month, Baylor Scott & White Research Institute enrolled the first four patients in the world on Gilead’s new clinical trial involving an investigational inhaled solution of remdesivir (NCT04539262). This is Gilead’s first trial in COVID-19 patients examining the safety and efficacy of an inhaled solution of the drug in an outpatient setting. The study of an inhaled solution asks whether this mode of delivery can help reduce the amount of virus from the airways earlier.
Rutgers School of Public Health, Rutgers New Jersey Medical School, and the North Jersey Community Research Initiative, have launched a study to determine the presence of SARS-CoV-2 (COVID-19) antibodies among Essex County residents using seroprevalence testing.
The Clinical Laboratories of The Mount Sinai Hospital has received emergency use authorization from the New York State Department of Health (NYSDOH) for quantitative use of Mount Sinai’s COVID-19 antibody test, making Mount Sinai’s lab the first in the country to run an authorized, fully quantitative antibody test that can deliver a precise numeric measurement of the level of antibodies in a patient’s blood
A study on the effectiveness of multiple treatments, including laboratory-made antibodies, at preventing mild COVID-19 from advancing to severe illness in the outpatient setting is underway by researchers at The University of Texas Health Science Center at Houston (UTHealth). The clinical trial is enrolling patients at Harris Health System’s Lyndon B. Johnson Hospital.
A study released by Houston Methodist Sept. 10 in the Journal of Clinical Investigation takes researchers closer to developing a uniform, universal COVID-19 antibody test. The multicenter collaboration tested alternative ways to measure COVID-19 antibody levels that’s faster, easier and can inexpensively be used on a larger scale to accurately identify potential donors for plasma therapy with the best chance of helping patients infected with SARS-CoV-2.
Researchers at The Rockefeller University in New York have developed new tools to rapidly test the ability of antibodies to neutralize SARS-CoV-2, the novel coronavirus responsible for the COVID-19 pandemic. The approach, described today in the Journal of Experimental Medicine (JEM), will help researchers understand whether patients are susceptible to reinfection by SARS-CoV-2 and assess the effectiveness of experimental vaccines, as well as develop antibody-based therapies against the disease.
Research from the Mount Sinai Health System, just posted to pre-print server MedRxiv (https://www.medrxiv.org/content/10.1101/2020.07.14.20151126v1), shows that the vast majority (more than 90%) of infected individuals with mild-to-moderate COVID 19 experience robust IgG antibody responses against the viral spike protein. The researchers also show…